Roger Kornberg - Protalix Biotherapeutics Independent Director
| PLX Stock | USD 1.13 0.02 1.74% |
Director
Mr. Dror Bashan was appointed President, Chief Executive Officer and Director at Protalix BioTherapeutics, Inc. effective June 30, 2019. His work experience includes the following roles Holder of a number of senior executive roles at Teva Pharmaceutical Industries Limited and Tevas Senior Vice PresidentGlobal Business Development. He holds a Bachelors degree in Economics and Business Administration and a MBA degree, both from Tel Aviv University. since 2019.
| Age | 68 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | Science Park, Karmiel, Israel, 2161401 |
| Phone | 972 4 902 8100 |
| Web | https://www.protalix.com |
Roger Kornberg Latest Insider Activity
Tracking and analyzing the buying and selling activities of Roger Kornberg against Protalix Biotherapeutics stock is an integral part of due diligence when investing in Protalix Biotherapeutics. Roger Kornberg insider activity provides valuable insight into whether Protalix Biotherapeutics is net buyers or sellers over its current business cycle. Note, Protalix Biotherapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Protalix Biotherapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Roger Kornberg over three weeks ago Acquisition by Roger Kornberg of 25000 shares of Xenetic Biosciences subject to Rule 16b-3 | ||
Roger Kornberg over three months ago Acquisition by Roger Kornberg of 2500 shares of Xenetic Biosciences subject to Rule 16b-3 |
Protalix Biotherapeutics Management Efficiency
The company has Return on Asset of 0.0933 % which means that on every $100 spent on assets, it made $0.0933 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.725 %, implying that it generated $0.725 on every 100 dollars invested. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.28 in 2024, whereas Return On Equity is likely to drop 0.24 in 2024. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.10 in 2024, whereas Total Assets are likely to drop slightly above 51 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Bosen | Provident Bancorp | 49 | |
| Walter Colquitt | Home Federal Bancorp | 72 | |
| Jay Gould | Provident Bancorp | N/A | |
| Timothy Wilhite | Home Federal Bancorp | 48 | |
| Clyde Patterson | Home Federal Bancorp | 74 | |
| Wayne Tatro | Provident Bancorp | 72 | |
| Lisa DeStefano | Provident Bancorp | N/A | |
| Scott Lawrence | Home Federal Bancorp | 71 | |
| Woodus Humphrey | Home Federal Bancorp | 77 | |
| Andres Chevallier | Betterware De Mexico | 40 | |
| Laurie Knapp | Provident Bancorp | 56 | |
| Thomas Trawick | Home Federal Bancorp | 48 | |
| Frank Cousins | Provident Bancorp | 55 | |
| Arthur Sullivan | Provident Bancorp | N/A | |
| Richard Peeke | Provident Bancorp | 69 | |
| Eduardo Szymanski | Betterware De Mexico | N/A | |
| David Herndon | Home Federal Bancorp | 79 | |
| Mari Cano | Betterware De Mexico | N/A | |
| Mark Harrison | Home Federal Bancorp | 58 | |
Management Performance
| Return On Equity | 0.73 | ||||
| Return On Asset | 0.0933 |
Protalix Biotherapeutics Leadership Team
Elected by the shareholders, the Protalix Biotherapeutics' board of directors comprises two types of representatives: Protalix Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protalix. The board's role is to monitor Protalix Biotherapeutics' management team and ensure that shareholders' interests are well served. Protalix Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protalix Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Kornberg, Independent Director | ||
| Eyal MBA, CFO, VP | ||
| Yoseph Shaaltiel, Founder and Executive VP of RandD | ||
| Shlomo Yanai, Chairman of the Board | ||
| Yaron Naos, Senior Vice President - Operations | ||
| Amos BarShalev, Independent Director | ||
| Tzvi Palash, COO | ||
| Yael Fellous, Vice Resources | ||
| Dror Bashan, President CEO | ||
| Aharon Schwartz, Independent Director | ||
| Zeev Bronfeld, Independent Interim Chairman of the Board | ||
| Einat Almon, Sr. VP of Product Devel. | ||
| Yossi Maimon, CFO, Vice President Treasurer, Secretary | ||
| David Granot, Independent Director | ||
| Marcy Nanus, Investor Contact | ||
| Moshe Manor, CEO and President and Director | ||
| Yodfat Buchris, Independent Director |
Protalix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protalix Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.73 | ||||
| Return On Asset | 0.0933 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 65 M | ||||
| Shares Outstanding | 73.05 M | ||||
| Shares Owned By Insiders | 9.76 % | ||||
| Shares Owned By Institutions | 14.03 % | ||||
| Number Of Shares Shorted | 6.46 M | ||||
| Price To Earning | (1.23) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protalix Biotherapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protalix Biotherapeutics' short interest history, or implied volatility extrapolated from Protalix Biotherapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protalix Biotherapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Protalix Stock analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 0.09 | Revenue Per Share 0.97 | Quarterly Revenue Growth 0.217 | Return On Assets 0.0933 |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.